Abstract:
:With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transplants offer enhanced overall patient survival by reducing waiting times. ECD kidneys may be more susceptible to toxicity associated with calcineurin inhibitors (CNIs); therefore, a potential strategy to improve outcomes in this growing demographic is the use of CNI-free immunosuppressive protocols. To date, published clinical studies have demonstrated encouraging outcomes using sirolimus-based CNI-free regimens in SCD kidney transplant recipients. We conducted a pilot study to examine outcomes in ECD kidney transplant recipients receiving a CNI-free quadruple drug regimen, consisting of antithymocyte globulin (ATG), sirolimus, mycophenolate mofetil (MMF) and a corticosteroid, compared with outcomes in a retrospective CNI-control group of ECD recipients who had received standard CNI-based immunosuppressive treatment. Patient survival and allograft survival at 1 year were not significantly different between the CNI-free group (n = 13) and the CNI-control group (n = 13) [100% vs 92% and 92% vs 85%, respectively]; nor was the incidence of rejection (26% and 31%) or delayed graft function (38% of patients in both groups). Serum creatinine was significantly lower and the estimated glomerular filtration rate was significantly higher for the CNI-free group at 3-6 months but not at 1 year. Protocol biopsies in the CNI-free patients at 1 year revealed no significant progression of chronic vascular lesions. Banff chronic/sclerosing allograft nephropathy scores were 42% grade I, 25% grades II and III, and 33% grade 0. Thus, a sirolimus-based CNI-free regimen may improve outcomes in ECD kidney transplant recipients and merits further study.
journal_name
Drugsjournal_title
Drugsauthors
House AA,Nguan CY,Luke PPdoi
10.2165/00003495-200868001-00006subject
Has Abstractpub_date
2008-01-01 00:00:00pages
41-9eissn
0012-6667issn
1179-1950pii
6816journal_volume
68 Suppl 1pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00046
更新日期:1987-01-01 00:00:00
abstract::Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550050-00006
更新日期:1995-11-01 00:00:00
abstract::Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161040-00004
更新日期:2001-01-01 00:00:00
abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666020-00002
更新日期:2006-01-01 00:00:00
abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464230-00005
更新日期:2004-01-01 00:00:00
abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11585440-000000000-00000
更新日期:2011-05-07 00:00:00
abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/10489100-000000000-00000
更新日期:2009-11-12 00:00:00
abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161001-00005
更新日期:2001-01-01 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262010-00007
更新日期:2002-01-01 00:00:00
abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565140-00004
更新日期:2005-01-01 00:00:00
abstract::Accumulating evidence suggests the involvement of estrogen in depression. Estrogen can modulate neurotransmitter turnover, enhancing the levels of serotonin and noradrenaline (norepinephrine), and it is involved in the regulation of serotonin receptor number and function. Across the female reproductive life, fluctuati...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11635960-000000000-00000
更新日期:2012-09-10 00:00:00
abstract::Depression is associated with a risk of suicide 13 to 30 times greater than in the general population, and antidepressants are among the drugs most frequently implicated in fatal overdose, resulting in a dilemma for the clinician. Suicidal thoughts are a core symptom of depression, and there is evidence that the selec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200432-00005
更新日期:1992-01-01 00:00:00
abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11591500-000000000-00000
更新日期:2011-05-28 00:00:00
abstract::Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which, during continuous administration, down-regulates the pituitary-ovarian gonadal axis and reduces levels of the gonadotrophins, luteinising hormone and follicle-stimulating hormone. In women, this results in suppression of ovarian steroidogenesis and ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199651020-00009
更新日期:1996-02-01 00:00:00
abstract::The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 m...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199300461-00059
更新日期:1993-01-01 00:00:00
abstract::The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753040-00003
更新日期:1997-04-01 00:00:00
abstract::The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0376-z
更新日期:2015-04-01 00:00:00
abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-018-1009-0
更新日期:2018-11-01 00:00:00
abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00013
更新日期:1988-01-01 00:00:00
abstract::The benefits of the treatment of hypertension currently consist of a substantially reduced incidence of premature stroke, left ventricular failure and malignant hypertension. The benefits for the individual are most clearcut in those who have already had severe or symptomatic hypertension. Older subjects who have a hi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800366-00003
更新日期:1988-01-01 00:00:00
abstract::Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The pathogenesis of HE in cirrhosis is complex and multifactorial, but a key role i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/10898630-000000000-00000
更新日期:2010-06-18 00:00:00
abstract::Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666120-00009
更新日期:2006-01-01 00:00:00
abstract::The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199700545-00003
更新日期:1997-01-01 00:00:00
abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957060-00002
更新日期:1999-06-01 00:00:00
abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199448040-00006
更新日期:1994-10-01 00:00:00
abstract::Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0756-7
更新日期:2017-06-01 00:00:00
abstract::Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363100-00004
更新日期:2003-01-01 00:00:00
abstract::The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198325050-00003
更新日期:1983-05-01 00:00:00